pharmaphorum July 30, 2024
It’s possible that Alzheimer’s disease could be added to the lengthening list of health conditions that can be improved by treatment with GLP-1 receptor agonists.
The phase 2 ELAD study of Novo Nordisk’s once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer’s has shown that the drug was able to reduce shrinking in the areas of the brain that control memory, learning, language and decision-making by nearly 50% compared to placebo.
Moreover, subjects taking liraglutide saw an 18% slower cognitive decline after a year’s treatment compared to the control group, according to data presented at the Alzheimer’s Association International Conference (AAIC) today.
Liraglutide is on the market as Victoza for diabetes and Saxenda for obesity. It has been largely...
Today's Sponsors
Today's Sponsor